Obesity & Overweight
Conditions
Keywords
WEGOVY®, sémaglutide 2,4 mg, Obesity, Overweight, ATU
Brief summary
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.
Interventions
OTHERSEMAFOLLOW questionnaire
If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes
Sponsors
Nantes University Hospital
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY * No objection to the use of their data * Patients able to complete an online questionnaire (via the internet)
Exclusion criteria
• Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Describe weight changes during the follow-up period according to patient characteristics. | Baseline |
Secondary
| Measure | Time frame |
|---|---|
| Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors. | Baseline |
| Compare the profiles of responders and non-responders | Baseline |
| Describe weight change according to different subpopulations. | Baseline |
Countries
France
Contacts
CONTACTDavid JACOBI
STUDY_DIRECTORDavid JACOBI
Nantes University Hospital
Outcome results
None listed